ASCLETIS-B (01672) announced that on February 3, 2026, the company proposes to place 69.256 million shares, representing approximately 6.98% of the company's issued share capital as of the date of this announcement (which is 992 million shares, excluding 7.0842 million treasury shares).

The placing price is set at HK$12.18 per share, representing a discount of approximately 4.0% to the closing price of HK$12.69 per share on February 2.

The gross proceeds from the placing are expected to amount to approximately HK$843.5 million, while the net proceeds are anticipated to be approximately HK$835.3 million.

Approximately 90% of the net proceeds from the placing are intended to be used for the preparation, foundational work, and initiation of the global Phase III clinical trial for ASC30, an oral small-molecule GLP-1 receptor agonist for the treatment of obesity.

Approximately 10% of the net proceeds from the placing are proposed to be used as working capital and for other general corporate purposes.